Synthesis and evaluation of a novel deguelin derivative, L80, which disrupts ATP binding to the C-terminal domain of heat shock protein 90

Molecular Pharmacology

Volumn 88, Issue 2, 2015, Pages 245-255

  Lee, Su Chan ^a   Min, Hye Young ^a   Choi, Hoon ^a   Kim, Ho Shin ^a   Kim, Kyong Cheol ^a   Park, So Jung ^b   Seong, Myeong A ^a   Seo, Ji Hae ^a   Park, Hyun Ju ^b   Suh, Young Ger ^a   Kim, Kyu Won ^a   Hong, Hyun Seok ^c   Kim, Hee ^c   Lee, Min Young ^c   Lee, Jeewoo ^a   Lee, Ho Young ^a  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Medifron DBT ^*  (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

(6,7-DIMETHOXYQUINOLIN-4-YL)(5-METHOXY-2,2-DIMETHYL-2H-CHROMEN-6-YL)METHYL ACETATE; ANTINEOPLASTIC AGENT; BENZOPYRAN DERIVATIVE; DEGUELIN; HEAT SHOCK PROTEIN 90; QUINOLINE DERIVATIVE; ROTENONE;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; LUNG NEOPLASMS; METABOLISM; MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; QUINOLINES; ROTENONE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939802118     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.096883     Document Type: Article

References (50)

1. Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, Zhang C, Wada Y, and Proia DA (2012) Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 11:2633-2643.
2. Bagatell R and Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3:1021-1030.
3. Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, and Samson M et al. (2009) Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther 8:3296-3306.
4. Boreddy SR and Srivastava SK (2013) Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model. Oncogene 32:3980-3991.
5. Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J, and Blagg BS (2008) Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem 73:2130-2137.
6. Burlison JA, Neckers L, Smith AB, Maxwell A, and Blagg BS (2006) Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc 128:15529-15536.
7. Caboni P, Sherer TB, Zhang N, Taylor G, Na HM, Greenamyre JT, and Casida JE (2004) Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem Res Toxicol 17:1540-1548.
8. Chang DJ, An H, Kim KS, Kim HH, Jung J, Lee JM, Kim NJ, Han YT, Yun H, and Lee S et al. (2012) Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis. J Med Chem 55:10863-10884.
9. Chun KH, Kosmeder JW, 2nd, Sun S, Pezzuto JM, Lotan R, Hong WK, and Lee HY (2003) Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 95:291-302.
10. Di L, Kerns EH, Fan K, McConnell OJ, and Carter GT (2003) High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38:223-232.
11. Dobbelstein M and Moll U (2014) Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 13:179-196.
12. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, and Avsar E et al. (2013) The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther 12:890-900.
13. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
14. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, and Neckers LM (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936-29944.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
16. Jhaveri K, Taldone T, Modi S, and Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823:742-755.
17. Kanamaru C, Yamada Y, Hayashi S, Matsushita T, Suda A, Nagayasu M, Kimura K, and Chiba S (2014) Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs. J Toxicol Sci 39:59-69.
18. Kang HW, Kim JM, Cha MY, Jung HC, Song IS, and Kim JS (2012) Deguelin, an Akt inhibitor, down-regulates NF-kB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Dig Dis Sci 57:2873-2882.
19. Kansy M, Senner F, and Gubernator K (1998) Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41:1007-1010.
20. Katschinski DM, Le L, Schindler SG, Thomas T, Voss AK, and Wenger RH (2004) Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1alpha stabilization. Cell Physiol Biochem 14: 351-360.
21. Kim WY, Chang DJ, Hennessy B, Kang HJ, Yoo J, Han SH, Kim YS, Park HJ, Seo SY, and Mills G et al. (2008) A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila) 1:577-587.
22. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu T, and Zaatar A et al. (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105:595-605.
23. Lee H, Lee JH, Jung KH, and Hong SS (2010) Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer. Oncol Rep 24:957-963.
24. Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran H, Pezzuto JM, and Moriarty RM et al. (2005) Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97:1695-1699.
25. Lee HY, Suh YA, Kosmeder JW, Pezzuto JM, Hong WK, and Kurie JM (2004) Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin Cancer Res 10: 1074-1079.
26. Marcu MG, Chadli A, Bouhouche I, Catelli M, and Neckers LM (2000a) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275:37181-37186.
27. Marcu MG, Schulte TW, and Neckers L (2000b) Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 92:242-248.
28. Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, Muzzio M, and Mehta RG (2013a) Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS ONE 8:e65113.
29. Mehta RR, Katta H, Kalra A, Patel R, Gupta A, Alimirah F, Murillo G, Peng X, Unni A, and Muzzio M et al. (2013b) Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells. Clin Exp Metastasis 30:855-866.
30. Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, and Michiels C (1999) Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 460:251-256.
31. Murillo G, Peng X, Torres KE, and Mehta RG (2009) Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res (Phila) 2:942-950.
32. Oh SH, Woo JK, Jin Q, Kang HJ, Jeong JW, Kim KW, Hong WK, and Lee HY (2008) Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer 122: 5-14.
33. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, and Kim KW et al. (2007) Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99:949-961.
34. Ramalingam S and Belani CP (2004) Paclitaxel for non-small cell lung cancer. Expert Opin Pharmacother 5:1771-1780.
35. Ratzke C, Mickler M, Hellenkamp B, Buchner J, and Hugel T (2010) Dynamics of heat shock protein 90 C-terminal dimerization is an important part of its conformational cycle. Proc Natl Acad Sci USA 107:16101-16106.
36. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, and Solit DB (2008) Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68:589-596.
37. Sgobba M, Degliesposti G, Ferrari AM, and Rastelli G (2008) Structural models and binding site prediction of the C-terminal domain of human Hsp90: a new target for anticancer drugs. Chem Biol Drug Des 71:420-433.
38. Sharma SV, Bell DW, Settleman J, and Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181.
39. Shimamura T and Shapiro GI (2008) Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol 3(Suppl 2): S152-159.
40. Siegel R, Naishadham D, and Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
41. Solár P, Horváth V, Kleban J, Koval' J, Solárová Z, Kozubík A, and Fedorocko P (2007) Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma 54:127-130.
42. Söti C, Rácz A, and Csermely P (2002) A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem 277:7066-7075.
43. Suh YA, Kim JH, Sung MA, Boo HJ, Yun HJ, Lee SH, Lee HJ, Min HY, Suh YG, and Kim KW et al. (2013) A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer. Cancer Lett 332:102-109.
44. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, and Giannakakou P et al. (2005) Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65:605-612.
45. Thamilselvan V, Menon M, and Thamilselvan S (2011) Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 beta/beta-catenin pathway. Int J Cancer 129: 2916-2927.
46. Trepel J, Mollapour M, Giaccone G, and Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537-549.
47. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, and Akimov M et al. (2013) Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther 12:509-519.
48. Whitesell L and Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772.
49. Woo JK, Choi DS, Tran HT, Gilbert BE, Hong WK, and Lee HY (2009) Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis. Cancer Prev Res (Phila) 2:361-369.
50. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, and Sun D (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7:162-170.